Acute Heart Failure Acute heart failure is defined as sudden change in heart functions (inability of heart to pump enough blood to meet body's demand). Symptoms include shortness of breath, weakness, fatigue, irregular or fast heartbeat and coughing and wheezing. Predisposing factors include high blood pressure, diabetes, coronary artery disease, inherited heart defects, and a damaged or inflamed heart. Treatment includes angiotensin-converting enzyme (ACE) inhibitors, beta blockers, diuretics and surgery.
Acute Heart Failure pipeline therapeutics constitutes close to 9 molecules. which approximately 9 molecules are developed by Companies. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 2 and 2 respectively.
Acute Heart Failure - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Acute Heart Failure and features dormant and discontinued projects.
Key Topics Covered:
- Acute Heart Failure Overview
- Therapeutics Development
- Pipeline Products for Acute Heart Failure - Overview
- Pipeline Products for Acute Heart Failure - Comparative Analysis
- Acute Heart Failure - Therapeutics under Development by Companies
- Acute Heart Failure - Therapeutics under Investigation by Universities/Institutes
- Acute Heart Failure Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Acute Heart Failure - Products under Development by Companies
- Acute Heart Failure - Products under Investigation by Universities/Institutes
- Acute Heart Failure - Companies Involved in Therapeutics Development
- Amgen Inc.
- Capricor Therapeutics, Inc.
- Eli Lilly and Company
- Lee's Pharmaceutical Holdings Limited
- Novartis AG
- Ono Pharmaceutical Co., Ltd.
- PhaseBio Pharmaceuticals, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/wjzg3g/acute_heart